Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate)
Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2003
Reference approved
Reference product
Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Jul 25, 2003
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Molecular structure
Experimental 3D structure for Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method from the RCSB Protein Data Bank (PDB 3CDZ).
Interactive biological assembly from PDB entry 3CDZ. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method, in chronological order.
Reference approval
Approval date of the reference Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method product.
23 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate)?
No 351(k) biosimilars or interchangeable biosimilars referencing Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.